Peelen T, van Vliet M, Bosch A, Bignell G, Vasen H F, Klijn J G, Meijers-Heijboer H, Stratton M, van Ommen G J, Cornelisse C J, Devilee P
Department of Human Genetics, Leiden University Medical Center, The Netherlands.
Br J Cancer. 2000 Jan;82(1):151-6. doi: 10.1054/bjoc.1999.0892.
We have analysed 81 families with a history of breast and/or ovarian cancer for the presence of germline mutations in BRCA2 with a number of different mutation screening techniques. The protein truncation test (PTT) for exons 10 and 11 detected four different frame-shifting mutations in six of these families. Four of the remaining 75 families had given positive linkage evidence for being due to BRCA2. In these families the entire coding region was analysed by single-strand conformational polymorphism, leading to the detection of a non-sense and a splice-site mutation in two of them. While these studies were in progress, Southern analysis of BRCA1 revealed that in our study-population of 81 families, 15 families were segregating either the exon 13 or exon 22 deletion in BRCA1 (Petrij-Bosch et al (1997) Nat Genet 17: 341-345). This prompted us to examine BRCA2 in the remaining 58 families by Southern analysis, using two different restriction enzymes. No aberrations were found in the restriction patterns. Thus, contrary to BRCA1, large genomic rearrangements within the BRCA2 gene do not represent a major mutation mechanism among Dutch breast cancer families.
我们运用多种不同的突变筛查技术,对81个有乳腺癌和/或卵巢癌家族史的家庭进行了分析,以检测BRCA2基因种系突变的存在情况。针对外显子10和11的蛋白质截短试验(PTT)在其中6个家庭中检测到4种不同的移码突变。其余75个家庭中有4个家庭给出了因BRCA2导致的阳性连锁证据。在这些家庭中,通过单链构象多态性分析了整个编码区,结果在其中2个家庭中检测到1个无义突变和1个剪接位点突变。在这些研究进行期间,对BRCA1的Southern分析显示,在我们的81个家庭研究群体中,有15个家庭在分离BRCA1的外显子13或外显子22缺失(Petrij - Bosch等人(1997年)《自然遗传学》17卷:341 - 345页)。这促使我们通过Southern分析,使用两种不同的限制酶,对其余58个家庭中的BRCA2进行检测。在限制酶切图谱中未发现异常。因此,与BRCA1不同,BRCA2基因内的大片段基因组重排在荷兰乳腺癌家族中并非主要的突变机制。